Kubitza, Dagmar <br/><br/>
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.  [electronic resource] 

 -  British journal of clinical pharmacology  Nov 2010 
 - 703-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2125 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2125.2010.03753.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Area Under Curve<br/>Cohort Studies<br/>Creatinine--metabolism<br/>Factor Xa Inhibitors<br/>Female<br/>Half-Life<br/>Humans<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Morpholines--pharmacokinetics<br/>Renal Insufficiency--metabolism<br/>Rivaroxaban<br/>Thiophenes--pharmacokinetics